Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

BACKGROUND: Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinostat in combination with imatinib (IM) for treatmen...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Bauer, S, Hilger, R A, Mühlenberg, T, Grabellus, F, Nagarajah, J, Hoiczyk, M, Reichardt, A, Ahrens, M, Reichardt, P, Grunewald, S, Scheulen, M E, Pustowka, A, Bock, E, Schuler, M, Pink, D
格式: Artigo
語言:Inglês
出版: Nature Publishing Group 2014
主題:
Clinical Study
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950855/
https://ncbi.nlm.nih.gov/pubmed/24434430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.826
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍